AwesomeCapital

Thursday, February 6, 2025

Trump lays out exactly how he plans for US to seize control of Gaza

President Trump on Thursday laid out how his proposed US takeover of the Gaza Strip would unfold, insisting it wouldn’t need military action and would ensure that “stability for the region would reign.”

“The Gaza Strip would be turned over to the United States by Israel at the conclusion of fighting,” Trump stated in an early morning Truth Social post.

“The Palestinians, people like Chuck Schumer, would have already been resettled in far safer and more beautiful communities, with new and modern homes, in the region,” he continued, with a knock on the Democratic New York senator.

“They would actually have a chance to be happy, safe, and free.”

Trump insisted that no American soldiers would be needed in his apparent plan of action.

“The U.S., working with great development teams from all over the World, would slowly and carefully begin the construction of what would become one of the greatest and most spectacular developments of its kind on Earth,” he said.

“No soldiers by the U.S. would be needed!”

It comes a day after the commander-in-chief laid bare the proposal and said that “all” Gaza Strip residents should leave the war-shattered territory.

Trump’s remarks came during his Oval Office meeting with Israeli Prime Minister Benjamin Netanyahu on Tuesday.

“The US will take over the Gaza Strip, and we will do a job with it too,” Trump said.

“We’ll own it and be responsible for dismantling all of the dangerous unexploded bombs and other weapons on the site, level the site, and get rid of the destroyed buildings — level it out and create an economic development that will supply unlimited numbers of jobs and housing for the people of the area.”

https://nypost.com/2025/02/06/world-news/trump-explains-exactly-how-he-plans-for-us-to-take-over-gaza/

At Least 40,000 Fed Workers Accept 'DOGE Buyout' As Deadline Looms Tonight

Thursday marked the final day for federal employees to accept the Trump administration's offer of eight months of pay and benefits in exchange for voluntarily stepping down. According to the latest figures from Bloomberg, at least 40,000 government workers—about 2% of the federal civilian workforce—have opted into the resignation program.

An official from the Office of Personnel Management told Bloomberg that deferred retirement applications have been steadily increasing and are expected to surge by the end of Thursday, the deadline to apply. Employees can submit their resignations by sending the word "resign" to their government email accounts.

"While a few agencies and even branches of the military are likely to see increases in the size of their workforce, the majority of federal agencies are likely to be downsized through restructurings, realignments, and reductions in force," OPM recently told federal workers in an email.

OPM added: "These actions are likely to include the use of furloughs and the reclassification to at-will status for a substantial number of federal employees."

The agency also told workers that "consolidation and divestitures" could lead to changes in "physical office" locations.

Reuters noted that federal worker unions have told members not to take the deal. The unions sued to block the offer, with a court hearing scheduled for 1300 ET. Also, Redditors on the "fednews" forum on the Reddit social media platform told other fed workers to "hold the line."

President Donald Trump and Elon Musk, a special government employee leading the Department of Government Efficiency, have been on a crusade to provide the American people with transparency regarding out-of-control spending by federal agencies. One major win for Trump has been unleashing DOGE to neuter the Deep State's unlimited piggybank, also known as USAID. The agency has since been rolled into the State Department.

Latest USAID headlines:

DOGE headlines:

The Trump administration estimated that between 5% and 10% of the federal workforce could accept the offer, which would save taxpayers close to $100 billion. This is what swamp draining looks like—a mandate the American people gave Trump.

https://www.zerohedge.com/political/least-40000-fed-workers-accept-doge-buyout-deadline-looms-tonight

Zelensky Demands NATO Give Ukraine Nukes

by Steve Watson via Modernity.news,

During an interview with Piers Morgan, Ukrainian President Volodymyr Zelensky suggested that NATO countries should supply his nation with nuclear weapons to deter Russia.

Not content with the billions in arms and munitions already sent his way, Zelensky inferred that the West should give them more.

Speaking of being a future member of NATO, the Ukrainian leader stated “NATO is not today, but in some time in the future, then all this process when we go to NATO, all this time when we are waiting, no matter how long it takes, and unfortunately, it does not depend on us.”

He continued, “If this process is protracted for years or decades, not because of us, but because of partners, then we have absolutely just question, what will be defending us against this evil for this whole time on this whole path?”

“Which support package, which missiles? Will we be given nuclear weapons?” Zelensky further asserted.

“Then let them give us nuclear weapons,” he added, further noting “Will they give us the missiles in the quantities that we can stop Russia? I’m not sure of that, but I think it would help. Otherwise, what missiles can stop Russia’s nuclear missiles?”

“Give us back nuclear arms,” Zelensky demanded, adding “give us missile systems, partners, help us finance the 1 million army, move your contingent on the parts of our state where we want the stability of the situation so that the people have tranquility.”

Yeah. Doesn’t seem like a very sound strategy does it?

Unless NATO wishes to speed up Armageddon.

As we highlighted earlier in the week, Zelensky has claimed that his country has received less than half of the $177 billion in aid agreed by the US under the Biden regime and that he doesn’t know where the rest of the money has gone.

* * *

https://www.zerohedge.com/geopolitical/zelensky-demands-nato-give-ukraine-nukes

Quantum Biopharma Licensee Celly Nutrition Eyes Possible IPO

BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to $10 million USD in capital and explore an initial public offering on a major US public exchange, subject to requisite regulatory approval.

Quantum BioPharma Ltd. retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

https://www.globenewswire.com/news-release/2025/02/06/3021946/0/en/Quantum-Biopharma-Licensee-Celly-Nutrition-Retains-Leading-New-York-Investment-Bank-to-Advise-on-Capital-Raise-and-Possible-Initial-Public-Offering-Following-Highly-Positive-Result.html

Lipella OKd on Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP).

LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies.

https://www.globenewswire.com/news-release/2025/02/06/3021821/0/en/Lipella-Pharmaceuticals-Granted-FDA-Approval-for-Expanded-Access-Program-for-LP-310-in-Oral-Lichen-Planus.html

Haemonetics cuts revenue outlook

While reporting financial results for the third quarter on Thursday, healthcare company Haemonetics Corp. (HAE) narrowed its adjusted earnings guidance range for the full-year 2025, while trimming revenue and organic revenue growth outlook.

For fiscal 2025, the company now projects adjusted earnings in a range of $4.50 to $4.70 per share on total revenue growth of 3 to 5 percent, with organic revenue growth of 0 to 3 percent.

Previously, the company expected adjusted earnings in a range of $4.45 to $4.75 per share on total revenue growth of 5 to 8 percent, with organic revenue growth of 1 to 4 percent.

https://www.rttnews.com/3510039/haemonetics-narrows-fy25-adj-eps-outlook-range-but-trims-revenue-growth-update.aspx

Lilly mixed earnings, ups guidance

Eli Lilly (LLY) reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trading. But the company missed on GLP-1 sales.

The pharma giant has had a few hits and misses in the past few months: its GLP-1 tirzepatide drugs removed from the FDA drug shortage list, which shuts down compounding pharmacy knockoffs, but also revising down its fourth quarter 2024 guidance last month, ahead of earnings Thursday.

The fourth quarter results showed a 45% increase in revenue, or $13.5 billion, from sales of its GLP-1 drugs — Mounjaro for diabetes and Zepbound for weight loss. Mounjaro brought in $11.5 billion alone, a 124% increase from 2023, and Zepbound totaled $4.9 billion. Still, the Mounjaro numbers missed Wall Street estimates but matched revised guidance.

Mizuho's healthcare sector expert Jared Holz wrote in a note to clients that Lilly remains the "preeminent growth story in large-cap pharma and one of the best in all of healthcare."

For the full year, Lilly reported $45 billion in revenue, up 32% from the prior year.

Lilly is one of two market leaders in the GLP-1 space, and is slowly gaining ground on Danish competitor Novo Nordisk (NVO), which reported record sales of GLP-1s Wednesday.

But the company is more than just a diabetes and obesity drug company, and that is where investors are focused for Lilly's long term prospects. In the last few years it has been favored as the potential first trillion-dollar health company due to GLP-1 profits. But its stock has come off last year's highs of $960 per share, currently trading at below $850 per share. Still, it remains one of the more highly valued big pharma companies.

Like its competitor, Lilly is also pursuing clinical trials in various other diseases for its GLP-1 drugs — which creates a larger potential patient population. It just received FDA approval for use as a sleep disorder drug.

Meanwhile, the company is also ahead of the pack in developing a pill option. Orforglipron is currently awaiting results of its Phase 3 trial and could be ready for the market by 2026.

"Beyond guidance, we think investor focus will be on mgmt commentary around TRx [prescription]/volume/coverage dynamics for Mounjaro/Zepbound as well as any color on orforglipron (which is expected to be filed in obesity in 2025)," JPM analyst Chris Schott wrote in a note to clients Thursday.

https://finance.yahoo.com/news/eli-lilly-reports-mixed-earnings-increases-2025-guidance-133811070.html

Search This Blog

Thursday, February 6, 2025